Terms: = Ovarian cancer AND KDR, VEGFR2, 3791, ENSG00000128052, P35968, VEGFR, CD309, FLK1 AND Treatment
136 results:
1. Combined inhibition of HER2 and vegfr synergistically improves therapeutic efficacy via PI3K-AKT pathway in advanced ovarian cancer.
Li W; Zhang K; Wang W; Liu Y; Huang J; Zheng M; Li L; Zhang X; Xu M; Chen G; Wang L; Zhang S
J Exp Clin Cancer Res; 2024 Feb; 43(1):56. PubMed ID: 38403634
[TBL] [Abstract] [Full Text] [Related]
2. Efficacy and safety of VEGF/vegfr inhibitors for platinum-resistant ovarian cancer: a systematic review and meta-analysis of randomized controlled trials.
Huang D; Ke L; Cui H; Li S; Sun F
BMC Womens Health; 2024 Jan; 24(1):34. PubMed ID: 38218775
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
4. A phase 1 trial of fuzuloparib in combination with apatinib for advanced ovarian and triple-negative breast cancer: efficacy, safety, pharmacokinetics and germline BRCA mutation analysis.
Liu Y; Wang W; Yin R; Zhang Y; Zhang Y; Zhang K; Pan H; Wang K; Lou G; Li G; Zhang R; Li K; Rao J; Zhang B; Wang Y; Wang Q; Gao Y; Li H
BMC Med; 2023 Sep; 21(1):376. PubMed ID: 37775744
[TBL] [Abstract] [Full Text] [Related]
5. Dynamic contrast-enhanced MRI to characterize angiogenesis in primary epithelial ovarian cancer: An exploratory study.
Lindgren A; Anttila M; Arponen O; Hämäläinen K; Könönen M; Vanninen R; Sallinen H
Eur J Radiol; 2023 Aug; 165():110925. PubMed ID: 37320880
[TBL] [Abstract] [Full Text] [Related]
6. Mass Spectrometry-Based Proteomics of Epithelial ovarian cancers: A Clinical Perspective.
Qian L; Sun R; Xue Z; Guo T
Mol Cell Proteomics; 2023 Jul; 22(7):100578. PubMed ID: 37209814
[TBL] [Abstract] [Full Text] [Related]
7. Angiogenesis inhibitors for the treatment of epithelial ovarian cancer.
Gaitskell K; Rogozińska E; Platt S; Chen Y; Abd El Aziz M; Tattersall A; Morrison J
Cochrane Database Syst Rev; 2023 Apr; 4(4):CD007930. PubMed ID: 37185961
[TBL] [Abstract] [Full Text] [Related]
8. Molecular cluster mining of high-grade serous ovarian cancer via multi-omics data analysis aids precise medicine.
Cai D; Liu T; Fang J; Liu Y
J Cancer Res Clin Oncol; 2023 Sep; 149(11):9151-9165. PubMed ID: 37178426
[TBL] [Abstract] [Full Text] [Related]
9. Observation of the therapeutic effect of apatinib in advanced platinum-resistant recurrent epithelial ovarian cancer.
Pan Z; Luo Z; He H; Chen Y; Zhao B; Yang Z; Li L
J Ovarian Res; 2023 Feb; 16(1):44. PubMed ID: 36823642
[TBL] [Abstract] [Full Text] [Related]
10. LncRNA H19 promotes tumor angiogenesis in smokers by targeting anti-angiogenic miRNAs.
Shirvaliloo M
Epigenomics; 2023 Jan; 15(2):61-73. PubMed ID: 36802727
[TBL] [Abstract] [Full Text] [Related]
11. An angiogenic tumor phenotype predicts poor prognosis in ovarian cancer.
Wieser V; Tsibulak I; Reimer DU; Zeimet AG; Fiegl H; Hackl H; Marth C
Gynecol Oncol; 2023 Mar; 170():290-299. PubMed ID: 36758419
[TBL] [Abstract] [Full Text] [Related]
12. [Anti-angiogenic drugs and hypertension: from multidisciplinary collaboration to greater care].
Tunesi F; Simonini M; Sabetta G; Bergamini A; Cioffi R; Raiabiotti E; Manunta P; Vezzoli G; Mangili G; Lanzani CL
G Ital Nefrol; 2022 Dec; 39(6):. PubMed ID: 36655833
[TBL] [Abstract] [Full Text] [Related]
13. Carboplatin enhances lymphocyte-endothelial interactions to promote CD8
Mark J; Fisher DT; Kim M; Emmons T; Khan ANMN; Alqassim E; Singel K; Mistarz A; Lugade A; Zhan H; Yu H; Segal B; Lele S; Frederick P; Kozbor D; Skitzki J; Odunsi K
Gynecol Oncol; 2023 Jan; 168():92-99. PubMed ID: 36410228
[TBL] [Abstract] [Full Text] [Related]
14. Anlotinib combined with TQB2450 in patients with platinum-resistant or -refractory ovarian cancer: A multi-center, single-arm, phase 1b trial.
Lan CY; Zhao J; Yang F; Xiong Y; Li R; Huang Y; Wang J; Liu C; Bi XH; Jin HH; Meng J; Zhao WH; Zhang L; Wang YF; Zheng M; Huang X
Cell Rep Med; 2022 Jul; 3(7):100689. PubMed ID: 35858589
[TBL] [Abstract] [Full Text] [Related]
15. Identification of key genes and pathways related to cancer-associated fibroblasts in chemoresistance of ovarian cancer cells based on GEO and TCGA databases.
Han L; Guo X; Du R; Guo K; Qi P; Bian H
J Ovarian Res; 2022 Jun; 15(1):75. PubMed ID: 35739532
[TBL] [Abstract] [Full Text] [Related]
16. Nivolumab, nivolumab-ipilimumab, and vegfr-tyrosine kinase inhibitors as first-line treatment for metastatic clear-cell renal cell carcinoma (BIONIKK): a biomarker-driven, open-label, non-comparative, randomised, phase 2 trial.
Vano YA; Elaidi R; Bennamoun M; Chevreau C; Borchiellini D; Pannier D; Maillet D; Gross-Goupil M; Tournigand C; Laguerre B; Barthélémy P; Coquan E; Gravis G; Houede N; Cancel M; Huillard O; Beuzeboc P; Fournier L; Méjean A; Cathelineau X; Doumerc N; Paparel P; Bernhard JC; de la Taille A; Bensalah K; Tricard T; Waeckel T; Pignot G; Braychenko E; Caruso S; Sun CM; Verkarre V; Lacroix G; Moreira M; Meylan M; Bougouïn A; Phan L; Thibault-Carpentier C; Zucman-Rossi J; Fridman WH; Sautès-Fridman C; Oudard S
Lancet Oncol; 2022 May; 23(5):612-624. PubMed ID: 35390339
[TBL] [Abstract] [Full Text] [Related]
17. Immune Mechanisms of Resistance to Cediranib in ovarian cancer.
Gopinathan G; Berlato C; Lakhani A; Szabova L; Pegrum C; Pedrosa AR; Laforets F; Maniati E; Balkwill FR
Mol Cancer Ther; 2022 Jun; 21(6):1030-1043. PubMed ID: 35313341
[TBL] [Abstract] [Full Text] [Related]
18. The Fibrillin-1/vegfr2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells.
Wang Z; Chen W; Zuo L; Xu M; Wu Y; Huang J; Zhang X; Li Y; Wang J; Chen J; Wang H; Sun H
Cancer Commun (Lond); 2022 Mar; 42(3):245-265. PubMed ID: 35234370
[TBL] [Abstract] [Full Text] [Related]
19. Proapoptotic Effect of Icariin on Human ovarian cancer Cells via the NF-[Formula: see text]B/PI3K-AKT Signaling Pathway: A Network Pharmacology-Directed Experimental Investigation.
Gao J; Fu Y; Song L; Long M; Zhang Y; Qin J; Liu H
Am J Chin Med; 2022; 50(2):589-619. PubMed ID: 35114909
[TBL] [Abstract] [Full Text] [Related]
20. Endothelial p130cas confers resistance to anti-angiogenesis therapy.
Wen Y; Chelariu-Raicu A; Umamaheswaran S; Nick AM; Stur E; Hanjra P; Jiang D; Jennings NB; Chen X; Corvigno S; Glassman D; Lopez-Berestein G; Liu J; Hung MC; Sood AK
Cell Rep; 2022 Jan; 38(4):110301. PubMed ID: 35081345
[TBL] [Abstract] [Full Text] [Related]
[Next]
